乳腺癌患者血清CEACAM1、SOST、P1NP与骨密度的关系及对骨质疏松症的预测价值  

Association of serum CEACAM1,SOST,and P1NP with bone mineral density in patients with breast cancer and predictive values for osteoporosis

作　　者：李双进 邢如温 侯勇强 魏彦 田文娟 王薇 LI Shuangjin;XING Ruwen;HOU Yongqiang;WEI Yan;TIAN Wenjuan;WANG Wei(Department of Orthopedic Surgery,Shijiazhuang Minghan Hosptial,Shijiazhuang 050035,Hebei,China;Department of General Surgery,Shijiazhuang Matemity and Child Healthcare Hosiptial,Shijiazhuang 050011,Hebei,China;Department of Orthopedics,BaodingYixianXinglin Hospital,Baoding 074200,Hebei,China;Department of Surgery,Zhengding People's hospital,Zhengding 050800,Hebei,China;Department of Oncology,the First Hospital of Hebei Medical University,Shijiazhuang 053300,Hebei,China)

机构地区：[1]石家庄明翰医院骨外科,河北石家庄050035 [2]石家庄市妇幼保健院普外科,河北石家庄050011 [3]保定易县杏林医院骨科,河北保定074200 [4]正定县人民医院外科,河北正定050800 [5]河北医科大学第一医院肿瘤科,河北石家庄053300

出　　处：《贵州医科大学学报》2024年第5期757-762,768,共7页Journal of Guizhou Medical University

基　　金：河北省2021年度医学科学研究课题计划[20210949]。

摘　　要：目的分析乳腺癌患者血清癌胚抗原相关细胞黏附分子1(CEACAM1)、骨标志物硬化蛋白(SOST)、Ⅰ型前胶原氨基端延长肽(P1NP)与骨密度的关系及对骨质疏松症的预测价值。方法选定52例乳腺癌患者进行回顾性研究,将其设为乳腺癌组,另选取同期本院乳腺专科接诊的50例乳腺良性增生患者,将其设为乳腺良性增生组,选取同期本院体检中心53例单纯绝经者,将其设为对照组;乳腺癌患者入院时均采用双能X线骨密度测量仪测量腰椎骨密度,依据骨密度将患者分为骨质疏松组(n=10)、骨密度低下组(n=36)、骨密度正常组(n=6);采用免疫发光法检测研究对象血清CEACAM1、P1NP水平,酶联免疫吸附法(ELISA)检测SOST水平;比较乳腺癌患者化疗前后血清CEACAM1、SOST、P1NP水平及腰椎骨密度,比较乳腺癌患者中不同骨密度组血清CEACAM1、SOST、P1NP水平;采用Pearson分析血清CEACAM1、SOST、P1NP水平与腰椎骨密度的关系,ROC曲线分析血清CEACAM1、SOST、P1NP水平对骨质疏松症的预测价值。结果乳腺癌组患者化疗前后血清CEACAM1水平、腰椎骨密度均低于乳腺良性增生组和对照组,而SOST、P1NP水平高于乳腺良性增生组和对照组(P<0.05);乳腺癌患者化疗后血清CEACAM1水平、腰椎骨密度值均低于化疗前,而血清SOST、P1NP水平均高于化疗前(P<0.05);乳腺癌骨质疏松组患者血清CEACAM1水平低于骨密度低下组和骨密度正常组(P<0.05),而血清SOST、P1NP水平高于骨密度低下组和骨密度正常组(P<0.05);血清CEACAM1水平与腰椎骨密度呈正相关性(r=0.405,P<0.05),血清SOST、P1NP水平与腰椎骨密度均呈负相关性(r=-0.399、-0.412,P<0.05);血清CEACAM1、SOST、P1NP水平联合检测预测骨质疏松症的AUC是0.799,(95%CI为0.721~0.957),灵敏度、特异度均高于单独检测(P<0.05)。结论乳腺癌患者血清CEACAM1、SOST、P1NP水平与骨密度存在一定的相关性,血清CEACAM1、SOST、P1NP水平联合检测�Objective To analyze the association of serum carcinoembryonic antigen-related cell adhesion molecule-1(CEACAM1),bone marker sclerotin(SOST),procollagen type I amino-terminal peptide(P1NP)and bone mineral density(BMD)in patients with breast cancer as well as the predictive value for osteoporosis.Methods Retrospective study was conducted on 52 patients with breast cancer,who were selected as breast cancer group.Additionally,50 patients with benign hyperplasia of the breast who were admitted to the department of breast at our hospital during the same period were selected as benign hyperplasia of the breast group,and 53 patients with simple menopause at the physical examination center of our hospital during the same period were selected as control group.All patients with breast cancer were measured by dual energy X-ray bone densitometer at admission.According to BMD,the patients were divided into osteoporosis group(n=10),low BMD group(n=36)and normal BMD group(n=6).Immunoluminescence was used to detect serum CEACAM1 and P1NP levels in research subjects.Enzyme linked immunosorbent assay(ELISA)was applied to detect SOST level.The levels of serum CEACAM1,SOST,P1NP,and lumbar spine BMD in the patients with breast cancer were compared before and after chemotherapy.Serum CEACAM1,SOST,and P1NP levels of the patients with breast cancer were compared among different BMD groups.Pearson correlation was conducted to analyze the association of serum levels of CEACAM1,SOST,and P1NP with lumbar spine BMD.ROC curve was used to analyze the predictive values of serum CEACAM1,SOST,and P1NP levels for osteoporosis.Results Serum CEACAM1 level and lumbar spine BMD before and after chemotherapy were lower in breast cancer group than those in benign hyperplasia of the breast and control groups,while the levels of SOST and P1NP were higher than those in benign hyperplasia of the breast and control groups(P<0.05).Serum CEACAM1 level and lumbar spine BMD of patients with breast cancer were lower after chemotherapy than those before chemothera

关 键 词：乳腺肿瘤 癌胚抗原相关细胞黏附分子1 骨标志物硬化蛋白 Ⅰ型前胶原氨基端延长肽 骨密度 

分 类 号：R737.9[医药卫生—肿瘤]